Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview

详细信息    查看全文

• 作者：Zachary R. Noel ; PharmD ; BCPS^a ; Craig J. Beavers ; PharmD ; AACC ; BCPS-AQ Cardiology ; CACP^b ; ^{cjbeav2@uky.edu}
• 关键词：Hyperlipidemia ; Low-density lipoprotein ; Proprotein convertase subtilisin/kexin type 9 ; Proprotein convertase subtilisin/kexin type 9 inhibitors
• 刊名：The American Journal of Medicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：130
• 期：2
• 页码：229.e1-229.e4
• 全文大小：157 K
• 卷排序：130

文摘

Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment.